Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells

Endocrinology

Volumn 153, Issue 10, 2012, Pages 4633-4643

  Heidegger, Isabel ^a   Ofer, Philipp ^a   Doppler, Wolfgang ^a   Rotter, Varda ^b   Klocker, Helmut ^a   Massoner, Petra ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GLUCOSE INTAKE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; HUMANS; INSULIN; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 84866762046     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1348     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 2011 Global cancer statistics. CA Cancer J Clin 61:69-90
2. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T 2009 Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56:594-605
3. Mohanty C, Das M, Kanwar JR, Sahoo SK 2011 Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv 8:45-58
4. Stavridi F, Karapanagiotou EM, Syrigos KN 2010 Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36:122-130
5. Heidegger I, Pircher A, Klocker H, Massoner P 2011 Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 11:701-701
6. Gualberto A, Pollak M 2009 Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28:3009-3021
7. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR 2005 In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11:3065-3074
8. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R 2003 An antiinsulin- like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083
9. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S., Strausz J, Gualberto A. 2010 Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 28(Suppl 15):7500 (Abstract)
10. Higano J, Alumkal CJ, Ryan E, Yu Y, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J, and the Prostate Cancer Clinical Trials Consortium 2009 A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC). J Clin Oncol 27(Suppl 15):5142 (Abstract)
11. Massoner P, Ladurner-Rennau M, Eder IE, Klocker H 2010 Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 103:1479-1484
12. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB 2005 Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145-153
13. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695
14. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
15. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V 2006 hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res 66:3531-3540
16. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS 1997 Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223
17. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z 2009 Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res 69:7375-7384
18. Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F 2004 Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 72:62-65
19. Ismail HA, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG2003 Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int 92:699-702
20. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG 2002 Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 87:726-728
21. Belfiore A 2007 The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671-686
22. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
23. Lemmon MA, Schlessinger J 2010 Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134
24. Cheng G, Kim MJ, Jia G, Agrawal DK 2007 Involvement of chloride channels in IGF-I-induced proliferation of porcine arterial smooth muscle cells. Cardiovasc Res 73:198-207
25. Petkov V, Stancheva S 1980 In vitro inhibition of cyclic 3′ 5′,-AMP-phosphodiesterase by a group of structural analogues of glaucine. Acta Physiol Pharmacol Bulg 6:38-47
26. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL 1997 Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138:1728-1735
27. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM 2008 Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68:3495-3504
28. Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstätter A, Summerer M, Reichhart E, Schäfer G, Klocker H 2011 Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment. Am J Pathol 179:2905-2919
29. Seino S, Bell GI 1989 Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 159:312-316
30. Valentinis B, Baserga R 2001 IGF-I receptor signalling in transformation and differentiation. Mol Pathol 54:133-137
31. Biedi C, Panetta D, Segat D, Cordera R, Maggi D 2003 Specificity of insulin-like growth factor I and insulin on Shc phosphorylation and Grb2 recruitment in caveolae. Endocrinology 144:5497-5503
32. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M 1996 Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 137:4427-4434
33. Dong JT 2006 Prevalent mutations in prostate cancer. J Cell Biochem 97:433-447
34. Shi R, Berkel HJ, Yu H 2001 Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85:991-996
35. Grimberg A, Cohen P 2000 Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9
36. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288
37. Pandini G, Medico E, Conte E, Sciacca L, Vigneri R, Belfiore A 2003 Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem 278:42178-42189
38. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A 2009 Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology 150:3594-3602
39. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM 1999 The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59:2203-2209
40. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928